Splenectomy for end-stage chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Surgical Oncology

Background:

• Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy.
• Advanced stages (III and IV) often present challenges in management, particularly when refractory to chemotherapy.
• Splenomegaly and cytopenias are common complications in advanced CLL.

Purpose of the Study:

• To evaluate the efficacy and safety of splenectomy in patients with advanced, chemotherapy-refractory chronic lymphocytic leukemia (CLL).
• To assess the impact of splenectomy on hematologic parameters and survival in this patient cohort.

Main Methods:

• Retrospective analysis of 13 patients with advanced (Stage III and IV) CLL who underwent splenectomy between February 1980 and December 1985.
• Patients had a median disease duration of 32 months and were refractory to chemotherapy.
• Hematologic parameters (hematocrit, platelet count) and survival were assessed pre- and post-splenectomy.

Main Results:

• Splenectomy was performed with no surgical mortality and minimal morbidity.
• Post-splenectomy, median hematocrit increased from 27.5% to 35% at 1 and 6 months.
• Median platelet count in thrombocytopenic patients rose significantly post-surgery, and median survival was 24 months, with four patients surviving over 30 months.

Conclusions:

• Splenectomy is a safe and effective procedure for managing advanced, chemotherapy-refractory chronic lymphocytic leukemia (CLL).
• The surgery leads to significant improvements in anemia and thrombocytopenia.
• Splenectomy serves as a valuable adjunct therapy, improving survival outcomes in end-stage CLL patients.